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Abstract
Background: notoriously known worldwide cause of morbidity and disability duodenal (DU) and gastric ulcer (GU) experi-
ence their rise in Ukraine, demonstrating formidable increase by 38,4 % in last decade with the prevalence of 2299 per 100 000 pop-
ulation. Every second patient is treated in-patiently, every third experiences disability spell annually. Reduction in related risks 
confined not so much by absence of effective therapy but rather shortcomings in patient management and patient devotion. By WHO 
data 50 % of patients fail to follow physician prescriptions, 60 % can’t recollect physician recommendations in first 20 minutes. 
Ubiquitous belated timing of rehabilitation initiation in post hospital stage appeared to be cardinal obstacle of its efficiency with low 
(up to 20 %) coverage, and ensuring clinical effect in 8 % cases only. 
Aim: to evaluate efficacy of rehabilitation program detailed at first episode of in-patient treatment at gastroenterological department. 
Data: organized by cohort design. Control cohort comprised 180 patients with first episode of hospitalization due to DU or 
GU in gastroenterological Vinnitsa city department in 2009–2010 years. Experimental cohort consisted of 220 alike patients who 
enter rehabilitation program (RP). RP was administered randomly. Randomness was statistically verified on principal confounders. 
Cases were traced 4 years. 
Methods: we applied three modifications of semi-parametric frailty model to study effect of program on the risk of recur-
rent hospitalization. 
Results: all three modifications coincided in that program secured typically at least 39 days to recurrent hospitalization per 
patient with drop in risk at least at RR=0,774.
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1. Introduction
By the literature review and our experience timing of rehabilitation administration is the 
crucial to sustain its efficiency in terms of coverage, adherence, and clinical effect. Innovative 
to clinical experience in Ukraine is shift in administration of rehabilitation to hospital stage. We 
also worked out extended program frame that combines 10 scales, namely medication of ulcer, 
diet modification, overweight control, physiotherapy exercises, management of NSAID-induced 
gastropathy, risk factor management, blood pressure correction, diabetes management, anxiety 
and depression management. To empower compliance and to facilitate case management we sup-
plied patient with diary and inculcate the skills of recording on drug intakes, unusual symptoms, 
complaints, as well as following indicated dates of examinations and physician referrals. The prime 
evidence of the efficacy of RP administration is the 4 % of dropouts only in first 3 months [1, 2].
2. Aim of research
Evaluate efficacy of rehabilitation program detailed at first episode of in-patient treatment 
at gastroenterological department.
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3. Materials and Methods
Design. Data organized by cohort design. Control cohort comprised 180 patients with first 
episode of hospitalization with DU or GU diagnoses in gastroenterological Vinnitsa city depart-
ment in 2009–2012 years. Experimental cohort consisted of 220 alike patients who enter RP. Pro-
gram was adminstered randomly. Randomness was statistically verified on principal confounders 
[3, 4]. Cases were traced for 4 years.
RP frame. RP frame combines 10 scales, namely medication of ulcer, diet modification, 
overweight control, physiotherapy exercises, management of NSAID-induced gastropathy, risk 
factor management, blood pressure correction, diabetes management, anxiety and depression man-
agement. Each scale has its content, detailed explanation of administration, check points, efficacy 
evaluation. For instance, we lay out medication scale composition. Others in details brought out 
elsewhere [5, 6].
Medication scale. Content. Assessment of patient condition, fibrogastroscopia, intragas-
tric pH monitoring, and H-pylori express diagnostic (De-Nol test) at hospitalization. Treatment of 
Hp-negative ulcers by antisecretory monotherapy starting with Group A1 – IPP of 1st generation 
(omeprazole 40 mg daily) during 4 weeks in case of duodenal ulcer and during 8 weeks in case 
of gastric ulcer. If prove to be ineffective in 10 days step to Group A2 – IPP of 3rd line in standard 
dosage (rabeprazole 20 mg daily), 4th line in standard dosage (pantoprazole 40 mg daily), 5th line in 
standard dosage (ezomeprazole 40 mg daily) during 4 weeks in case of duodenal ulcer and during 
8 weeks in case of gastric ulcer. In persevering casesdouble dosage of 3rd–5th lines of IPP drugs 
applied. In Hp-positive cases eradication of Н.pylori infection starts with B1 – 3rd–5th lines of IPP 
drugs (pantoprazole 20 mg twice a day,rabeprazole20 mg twice a day, esomeprazole 20 mg twice a 
day) + clarithromycin 500 mg twice a day + amoxicillin 1000 mg twice a day during 10 days and fol-
lows with administration of IPP drugs in standard dosages during 3 weeks in case of duodenal ulcer 
and during 6 weeks in case of gastric ulcer. If ineffective in 10 days step to B2 that is 3rd–5th lines of 
IPP drugs in standard dosages + tetracycline 500 mg 4 times a day + metronidazole 500 mg 3 times 
a day + bismuth subcitrate 120 mg 4 times a dayduring 10 days. Check points. Daily: self-control 
by indication of prescribed drugs intakes in diary. Weakly: assessment of clinical symptoms by 
general physician. Special points: evaluation of treatment efficacy at 10th day intragastric pH mon-
itoring in case of Hp-negative ulcers; evaluation ofН.pylori eradication in positive cases in two 
weeks upon treatment completion by fecal Н.рylori antigen test; visits to gastroenterologist upon 
1st and 2nd months. Efficacy evaluation. Patient follows prescribed therapy, admissible are 2 failures 
in day drug intake a month. Patient understands regimen of drug intakes. Achievement of clinical 
and endoscopic certified remission after 4 weeks of treatment: robust acid suppressive effect (рН>3) in 
10 days from the start of treatment with IPP; successful Н.pylori eradication in positive cases.
Follow up includes hospital and out of the hospital stages. To empower compliance and to 
facilitate case management we supplied patient with diary and inculcate the skills of recording on 
drug intakes, unusual symptoms, complaints, as well as following indicated dates of examinations 
and physician referrals. Diary proved to be helpful especially out of the hospital. The prime evi-
dence of the efficacy of RP administration is the 4 % of dropouts only in first 3 months.
We built efficacy estimation on time to next hospitalization that proved to be very sensitive 
to quality of care [7]. However, efficacy evaluation poses statistical challenge in part due to rana-
domization bias (e. g. self-selection bias), possible measurement error, or unavoidable presence of 
potent unobservable. So, treatment effect identification problem is conspicuous. We tackled it by 
control function technique [7, 8].
Model. We have chosen flexible semi-parametric frailty model to study modification effect 
of RP on the risk of recurrent hospitalization. Frailty model incapacitates the assessment of indi-
vidual propensity to “survive” till next hospitalization incorporating unobserved patient’s charac-
teristic influenced risk of recurrent hospitalization differently across patients. Overlooking frailties 
entails biased and inefficient estimation of survival effects [9]. Frailty model basically incorporates 
three main components: basic hazard function, changeable in time; function of factors, modifying 
basic hazard; frailty distribution. Hazard function is defined non-parametrically by exponential 
piece-wisepriors [10]. The number of time intervals defined by 0,25 quantiles of observed time 
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spans distribution that approximately coincides with monthly intervals. Pooling strength and iden-
tification of basic risks λj facilitated through RW1 process, namely (Win BUGS code):
lam[j]~dgamma(a0, b0[j])
b0[j] <- a0/lam[j-1]
lam[1]~dgamma(0.1,0.1),
a0~dgamma(0.1,0.1)
So that pooling is defined by gamma distribution with two first moments 0 and (λj-1)
2/a0.Risk 
is defined as proportional to basic, modified by exponent of observable covariates effect βj ⋅ xi:
                                          (( ) ( )i j 1 j i j j ih t q ,q | x exp x− ∈ = λ β ⋅ ,
where βj ⋅ xi is expressed by RP effect (parameter beta), bias in randomization of RP administration 
across patients (beta2), and individual random effects (frailties bj):
beta*Treatment + beta2*Treatment*bj + bj.
The principal parameter to test АТЕ (average treatment effect) [11, 12] is beta coefficient, 
purged from possible randomization flaws of patient selection to RP prescription by present 
beta2*Treatment*bj component, that is the control function. bj render individual patient’s effect 
with expected zero value, achieved by priors generation mechanism (rendered by b[j]~dnorm 
(0, tau) in program script). Individual patient’s effect includes all possible fixed individual effects 
both observable and unobservable. Presence of the latter is crucial for bias minimization in RP 
effect testing. Insignificant beta2 bares evidence on negligibility of bias in АТЕ estimation due to 
randomization flaws of patient selection to RP administration.
Cumulative risk (defined in programscript byН0) was calculated as integration of point risk
(( )i j 1 j ih t q ,q | x− ∈  on quantiles bounded time interval qj– qj-1as follows:
(( ) ( ) ( ) ( )j j 1 j j j 1 j j i j j 1H0 h t q ,q | x * q q exp x * q q− − −= ∈ − = λ β ⋅ − .
Survival functions in experimental and control cohorts members(defined in program code 
by S[1] and S[2]) were calculated by formulas:
                                                                                          ,
exp(beta)
40
j
j 1
40
j
j 1
S[1] exp H0
S[2] exp H0
=
=
  
= −     
 
= −  
∑
∑                                                                              .
Implementation and programming.
Powerful modern tool to implement hierarchical mixt models proved to be МСМС mod-
elling. We opted for convenient Gibbssampler. Programming performed in WinBUGS (Bayesian 
inference using Gibbs software) environment [13]. Data preparation as well as convergence diag-
nostics have been performed in environment of Rv.3.1.0 package CODA [14]. Displayed graphics 
were created by R package GRAPHICS. Program script is given below. It works in R environment. 
Script, data, initial values are passed to and processed by WinBUGS, activated through call «bugs» 
of R package R2WinBUGS.
Sampled values are returned to Rasspecial WinBUGS class object (named «results» in the script).
pkg<- «R2WinBUGS»
library(pkg, character.only = TRUE)
WD<-»C:/Dissertations/Natasha/NatashaGL5»
TD <- getwd()
if(!is.null(WD) & WD!=TD) setwd(WD)
data<-read.table(«GastroStacked.txt», header = TRUE)
model.file<- «Model/WinBugModel.txt»
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cat(«model {
for (i in 1:I){ 
TI[i]<-Treatment[i]*b[Patient[i]]
for (k in 1:K-1) {# risk status for subject i at interval k,
y[i,k] <- step(Tbetw [i] - a[k])*step(a[k+1] - Tbetw[i])
# times pentininterval k
o[i,k] <- (min(Tbetw [i], a[k+1]) - a[k])*step(Tbetw [i] - a[k])
# piecewiseexponential
theta[i,k] <- lam[k]*exp(beta*Treatment[i]+beta2*TI[i]+ b[Patient[i]])
mu[i,k] <- o[i,k]*theta[i,k]; y[i,k] ~dpois(mu[i,k]);
# likelihood (nuusedtoavoidlogsofzero)
nu[i,k] <- equals(mu[i,k],0) +(1-equals(mu[i,k],0))*mu[i,k]
LL[i,k] <- y[i,k]*log(nu[i,k])-mu[i,k]-logfact(y[i,k])}}
# multi-levelvariation: Patienteffects
for (j in 1:NUM) {b[j]~dnorm(0,tau); b.r[j] <- b[j]-mean(b[])}
tau~dgamma(1, 0.01)
sig<- 1/sqrt(tau)
# Gammaprocesspriorsonbaselinehazard
for (k in 2:K-1) {lam[k]~dgamma(a0, b0[k]); b0[k] <- a0/lam[k-1]}
lam[1]~dgamma(0.1,0.1)
# treatmentparameter
beta~dnorm(0, 0.001); beta2~dnorm(0, 0.001); a0~dgamma(0.1,0.1)
# CumHazardandSurvivorship
H0[1] <- lam[1]*a[1]; for (k in 2:K-1) {H0[k] <- lam[k]*(a[k]-a[k-1])}
for (j in 1:K-1) {S[1,j] <- pow(exp(-sum(H0[1:j])), exp(beta))
S[2,j] <- exp(-sum(H0[1:j]))}
# deviance
Dv<- -2*sum(LL[,])}», file=model.file)
q<-quantile(data$Tbetw, probs = seq(0, 100, by=2.5)/100)
q<-as.numeric(q)
K<-length(q)
I <- nrow(data)
PatientNumber<-400
Tbetw<-data$Tbetw
Treatment<-data$Treatment
Patient<-data$Patient
data<- list(a=q, K=K, I=I, NUM=PatientNumber, Tbetw=Tbetw, Treatment=Treatment, Pa-
tient=Patient) 
inits<- function(){
list(b=rep(0, times=PatientNumber), lam=rep(1, times=K-1), tau=1, a0=1, beta=0, beta2=0) }
parameters<- c(«beta», «beta2», «lam», «sig», «a0», «S», «Dv») 
results<- bugs(data=data, inits=inits, parameters.to.save=parameters, 
model=»WinBugModel.txt», debug=TRUE,
n.chains=1, n.iter=10000, bugs.seed=1966,
bugs.directory=»c:/Bugs/WinBUGS14»,
working.directory=»Model»,
clearWD=FALSE,
DIC=FALSE,
codaPkg=FALSE)
#convergencydiagnostics: Geweke’s,HeidelbergerandWelch’sconvergencediagnostictests: 
codat<-read.coda(output.file=»Model/coda1.txt», index.file=»Model/codaIndex.txt»)
geweke<-geweke.diag(codat, frac1=0.1, frac2=0.5)
z<-geweke$z
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i<-array(81:123)
z<-z[i]
heidel<-heidel.diag(codat, eps=0.1, pvalue=0.05)
raftery<-raftery.diag(codat, q=0.025, r=0.005, s=0.95, converge.eps=0.001)
4. Results 
Distribution of time spans (in days) to recurrent hospitalisation is displayed in Fig. 1. Dis-
tribution demonstrates right skew and conspiquous deviation from normality that in part calls for 
non-parametric approach [15]. Advantages of МСМС modelling also include capability of yielding 
posterior distributions of parameters of sampled values. We opted to display 5 % (0,05) and 95 % 
(0,95) centiles of posterior distributions of sampled parameters values (Table 1) along with conver-
gence diagnostics tests (Geweke’s Zand Heidelberg –Welchhalfwidth value).
Fig. 1. Distribution of time spans to recurrent hospitalisation
Table 1
Centiles values of posterior distributions of sampled parameters values with convergence 
diagnostics tests
Parameters
Centiles values Convergence tests
0,05 Median 0,95 Geweke’s Z H–W hl
Beta –0,4010 –0,2363 –0,0701 1,08 0,007660
beta2 –9,397 0,8838 8,525 –0,12 0,012200
λ1 0,0009 0,0017 0,0028 0,78 0,000035
λ2 0,0008 0,0011 0,0016 –0,20 0,000015
λ3 0,0009 0,0014 0,0021 –0,25 0,000022
λ38 0,0027 0,0039 0,0059 –1,84 0,000071
λ39 0,0036 0,0054 0,0078 –1,05 0,000169
λ40 0,0051 0,0081 0,0132 –1,71 0,000251
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The most important are parameters that actually estimate АТЕ of RP along with beta2 
that makes allowance for possible randomization flaws of patient selection to RP and corrects for 
bias the ATE estimate due to heterogeneity of control and experimental cohorts correlated with 
selection. According to the results the АТЕ is proved to be significant leaving beyond the limits of 
95 % posterior distribution interval [–0,4010; –0,0701] with median of –0,2363. Relative risk of RP 
administration on risk of recurrent hospitalization constituted ехр(–0,2363)=0,790. That is, risk of 
recurrent hospitalization reduced typically by 21 % by RP administration. 
Values of 5 % (0,05) and 95 % (0,95) centiles of posterior distribution of sampled beta2 vali-
ues negate the significance of randomizationbias effect, for 0 lays in the middle of 95 % posterior 
distribution interval which is [–9,397; 8,525]. Wide and symmetrical around posterior distribution 
95 % interval is conspicuous indication of the absence of randomization inconsistencies.We can 
suggest the absence of randomization induced bias in estimation of АТЕ that goes as corollary.
Median values of sampled values of basic risks of recurrent hospitalization on 40 time interu-
vals (λ1–λ40) stipulated conspicuous pattern with rise and leveling off from 18 to 32 months from 
discharge followed by bluff decline (Fig. 2). All basic risk estimates proved to be significant for all 
95 % confidence intervals of posterior distributions left zero beyond.
Fig. 2. Basic risks of recurrent hospitalization in 40 months 
Two survival curves tracing proportions of patients in experimental and control cohorts in 
wait of recurrent hospitalization built by the model (Fig. 3).Distinct patterns were observed with 
decreased survival among control cohort representatives. Cumulated difference appeared to be 
49 days per patient. This additional amount of days to next hospitalization safeguarded by RP that 
constitutes the effect of RP administration [16].
We also applied 2 extended models. Second one included important covariates in linear pre-
dictor. Only two covariates demonstrated marginally significant effect, namely GU with 95 % con-
fidence posterior interval of –0,140–0,890 and median 0,379, that is increased risk of 1,46 against 
DU, and regular visits to gastroenterologist with increased relative risk RR=1,24. RP effect with 
RR=0,762 saved 46 additional days to next hospitalization in average per patient. Still frailties 
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distribution persisted to be heterogeneous that was tackled by third model that implemented scale 
mixture priors of frailties [5]. 
Fig. 3. Survival curves tracing proportions of patients in experimental and control cohorts in wait 
of recurrent hospitalization 
The only significant fixed covariate effect rendered by contrast GU-DU. RP effect with 
RR=0,774 saved 39 additional days. Obtained results and model comparison (Table 2) supported 
robustness of RP administration effect [17].
Table 2
Effects of RP administration by 3 models
Characteristics Model #1 Model #2 Model #3
Information value, –2LL 4095 4074 3854
RR 0,790 0,762 0,774
Saved days 49 46 39
 
5. Discussion
Evaluation of recurrent hospitalization probability in patients with duodenal and gastric 
ulcer dependent upon rehabilitation input proved RP efficacy in terms of risk reduction by RR 
of 0,77–0,79. Given reduction secured 39–49 days to recurrent hospitalization. We rely on this 
measure of efficacy because episode of recurrent hospitalization is self-evident and uniformly reg-
istered, so measurement error, selectivity and reproducibility biases are minimized. Some may 
argues on economic efficiency assuming necessary increase in length of staying (LOS) and stip-
ulating so the full policy implications of our analysis are mixed. Indeed, an increase inpatients’ 
number of days in hospital is costly both in time and money, ceteris paribus. This is why a large 
number of health care policies such as the prospective payment system introduced in last decades 
mainly is aimed at reducing hospital LOS. On the other hand, such an increase may be partly justi-
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fied for two reasons. Firstly, it may be associated with more time spent by physicians on nonclinical 
activities such as teaching and administrative tasks, including rehabilitation efforts. Dumont, et. 
al., 2008 [18] provide evidence consistent with this effect as related to the Quebec reform. Second, 
as long as physicians spend more time treating their patients in hospital, this may improve patients’ 
health. That is exactly suggested by this paper since the risk of re-hospitalization significantly and 
systematically decreased.
Our results raise an important issue regarding the measure of health care services quality in 
a given patients. Does the decrease in the risk of readmission to hospital necessarily indicate a bet-
ter quality of services? We believe that this is the case still fretted with reservations. For instance, 
for a given diagnosis, physicians who spend more time with their patients in hospital to administer 
RP may also be more inclined to re-hospitalize them in order to provide them with a better treat-
ment or follow-up [19, 20]. A natural research extension of our paper could thus be to compare the 
evolution of health status of two random groups of patients with a same diagnosis but one treated 
with RP administration and the other one without.
6. Conclusions
1. Belated timing of rehabilitation initiation in post hospital stage appeared to be car-
dinal obstacle of its efficiency with low (up to 20 %) coverage, and securing clinical effect in 
8 % cases only.
2. We shifted administration of rehabilitation to hospital stage. Program frame combines 
10 scales, namely medication of ulcer, diet modification, overweight control, physiotherapy exer-
cises, management of NSAID-induced gastropathy, risk factor management, blood pressure correc-
tion, diabetes management, anxiety and depression management.
3. To empower compliance and to facilitate case management we supplied patient with diary 
and inculcate the skills of recording on drug intakes, unusual symptoms, complaints, as well as fol-
lowing indicated dates of examinations and physician referrals. The prime evidence of the efficacy 
of RP administration is the 4 % of dropouts only in first 3 months.
4. Program efficacy estimation relied upon time to recurrent hospitalization that proved to 
be very sensitive to quality of care. We have chosen flexible semi-parametric frailty models to 
study modification effect of program on the risk of recurrent hospitalization.
5. Results of three models coincided in that program secured typically at least 39 days to 
recurrent hospitalization per patient with drop in risk at least at RR=0,774. 
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